{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:27:33Z","timestamp":1790148453651,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI144182"],"award-info":[{"award-number":["U19 AI144182"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1145642"],"award-info":[{"award-number":["1145642"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health and Aged Care, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.048","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T18:25:45Z","timestamp":1690568745000},"page":"5553-5561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting"],"prefix":"10.1016","volume":"41","author":[{"given":"Thilini N.","family":"Padeniya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6567-5821","authenticated-orcid":false,"given":"Ben B.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-3528","authenticated-orcid":false,"given":"Kate L.","family":"Seib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.048_b0005","series-title":"Sexually Transmitted Diseases","author":"Holmes","year":"2008"},{"key":"10.1016\/j.vaccine.2023.07.048_b0010","unstructured":"Centers for Disease Control and Prevention. Gonorrhea \u2013 CDC Detailed Fact Sheet. 2022."},{"issue":"46","key":"10.1016\/j.vaccine.2023.07.048_b0015","article-title":"Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom","volume":"27","author":"Day","year":"2022","journal-title":"Euro Surveill"},{"issue":"11","key":"10.1016\/j.vaccine.2023.07.048_b0020","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/pathogens11111230","article-title":"Current susceptibility surveillance and distribution of antimicrobial resistance in N. gonorrheae within WHO Regions","volume":"11","author":"Radovanovic","year":"2022","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.048_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2023.07.048_b0030","unstructured":"World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact. 2021."},{"key":"10.1016\/j.vaccine.2023.07.048_b0035","unstructured":"World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012."},{"issue":"28","key":"10.1016\/j.vaccine.2023.07.048_b0040","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2020.02.073","article-title":"Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019","volume":"38","author":"Gottlieb","year":"2020","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.048_b0045","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/CVI.00230-16","article-title":"Summary and recommendations from the national institute of allergy and infectious diseases (NIAID) workshop \u201cGonorrhea Vaccines: the Way Forward\u201d","volume":"23","author":"Wetzler","year":"2016","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2023.07.048_b0050","unstructured":"World Health Organization. WHO preferred product characteristics for gonococcal vaccines. 2021."},{"issue":"10102","key":"10.1016\/j.vaccine.2023.07.048_b0055","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.048_b0060","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.048_b0065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","volume":"22","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.048_b0070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.048_b0075","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz1241","article-title":"Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics","volume":"71","author":"Whittles","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.048_b0080","doi-asserted-by":"crossref","unstructured":"Heijne JC. et al. The impact of vaccination on Neisseria gonorrhoeae antimicrobial resistance and prevalence in men who have sex with men: a mathematical modelling study. medRxiv, 2020: p. 2020.09.14.20192062 https:\/\/doi.org\/10.1101\/2020.09.14.20192062.","DOI":"10.1101\/2020.09.14.20192062"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.048_b0085","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/infdis\/jiab581","article-title":"A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men","volume":"225","author":"Hui","year":"2022","journal-title":"J Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2023.07.048_b0090","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2023.07.048_b0095","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1016\/j.vaccine.2022.10.031","article-title":"Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model","volume":"40","author":"Carey","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.048_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-022-14670-z","article-title":"The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study","volume":"23","author":"Looker","year":"2023","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.vaccine.2023.07.048_b0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2020.06.046","article-title":"Population prevalence of sexually transmitted infections in a high HIV burden district in KwaZulu-Natal, South Africa: Implications for HIV epidemic control","volume":"98","author":"Kharsany","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.048_b0110","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.07.048_b0115","unstructured":"The Joint United Nations Programme on HIV\/AIDS (UNAIDS). A snapshot of men and HIV in South Africa. 2017."},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.048_b0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94719-y","article-title":"COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact","volume":"11","author":"Swan","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.048_b0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1073\/pnas.1314688110","article-title":"Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model","volume":"111","author":"Warfel","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2023.07.048_b0130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3109\/1040841X.2015.1105782","article-title":"Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development","volume":"42","author":"Edwards","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2023.07.048_b0135","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2019."},{"key":"10.1016\/j.vaccine.2023.07.048_b0140","unstructured":"European Centre for Disease Prevention and Control. Gonorrhoea. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019."},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.048_b0145","doi-asserted-by":"crossref","first-page":"e1002511","DOI":"10.1371\/journal.pmed.1002511","article-title":"Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies","volume":"15","author":"Torrone","year":"2018","journal-title":"PLOS Med"},{"key":"10.1016\/j.vaccine.2023.07.048_b0150","unstructured":"World Health Organization (WHO). Global Health Sector Strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-202022."},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.048_b0155","doi-asserted-by":"crossref","first-page":"e0144869","DOI":"10.1371\/journal.pone.0144869","article-title":"Modelling the impact of condom distribution on the incidence and prevalence of sexually transmitted infections in an adult male prison system","volume":"10","author":"Scott","year":"2015","journal-title":"PLOS One"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.048_b0160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/sti.2003.007575","article-title":"Investigating ethnic inequalities in the incidence of sexually transmitted infections: mathematical modelling study","volume":"80","author":"Turner","year":"2004","journal-title":"Sex Transm Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2023.07.048_b0165","first-page":"639","article-title":"Epidemiology of sexually transmitted diseases: the global picture","volume":"68","author":"De Schryver","year":"1990","journal-title":"Bull World Health Organ"},{"issue":"38","key":"10.1016\/j.vaccine.2023.07.048_b0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1098\/rsif.2008.0394","article-title":"A metapopulation modelling framework for gonorrhoea and other sexually transmitted infections in heterosexual populations","volume":"6","author":"Chen","year":"2009","journal-title":"J R Soc Interface"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.048_b0175","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/cid\/ciw648","article-title":"The molecular epidemiology and antimicrobial resistance of Neisseria gonorrhoeae in Australia: A nationwide cross-sectional study, 2012","volume":"63","author":"Trembizki","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Supplement_1","key":"10.1016\/j.vaccine.2023.07.048_b0180","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","article-title":"Drugs of choice for the treatment of uncomplicated gonococcal infections","volume":"20","author":"Moran","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.048_b0185","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1086\/648428","article-title":"Pharyngeal gonorrhea: An important reservoir of infection?","volume":"49","author":"Weinstock","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2023.07.048_b0190","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1128\/JCM.05341-11","article-title":"Differing Neisseria gonorrhoeae bacterial loads in the pharynx and rectum in men who have sex with men: implications for gonococcal detection, transmission, and control","volume":"49","author":"Bissessor","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.07.048_b0195","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/infdis\/169.3.532","article-title":"Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development","volume":"169","author":"Cohen","year":"1994","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2023.07.048_b0200","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/OLQ.0b013e31820ff9a4","article-title":"The natural history of incident gonococcal infection in adolescent women","volume":"38","author":"Stupiansky","year":"2011","journal-title":"Sex Transm Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.07.048_b0205","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s10461-018-2300-5","article-title":"The context of sexual risk behaviour among men who have sex with men seeking PrEP, and the impact of PrEP on sexual behaviour","volume":"23","author":"Gafos","year":"2019","journal-title":"AIDS Behav"},{"issue":"2","key":"10.1016\/j.vaccine.2023.07.048_b0210","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1503\/cmaj.140900","article-title":"Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study","volume":"187","author":"Smith","year":"2015","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.048_b0215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amepre.2011.09.024","article-title":"Human papillomavirus vaccine and sexual behavior among adolescent and young women","volume":"42","author":"Liddon","year":"2012","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.07.048_b0220","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jamainternmed.2014.7886","article-title":"Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females","volume":"175","author":"Jena","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.07.048_b0225","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-155","article-title":"No difference in sexual behavior of adolescent girls following Human Papilloma Virus vaccination: a case study two districts in Uganda; Nakasongola and Luwero","volume":"14","author":"Aujo","year":"2014","journal-title":"BMC Publ Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:48Z","timestamp":1759404648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23008794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23008794"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}